The CiPA initiative began following a workshop in July 2013 at the US FDA. The objective of the CiPA initiative is to engineer an assay for assessment of the proarrhythmic potential of new drugs that has improved specificity compared with the hERG assay plus Thorough QT study.
Also known as: CIPA Initiative